Candel Therapeutics, Inc. (CADL) Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer May 15, 2026 1:00 PM EDT
Company Participants
Ted Jenkins
Paul-Peter Tak – President, CEO & Director
Garrett Nichols
William Garrett – Chief Medical Officer
Francesca Barone – Chief Scientific Officer
Seshu Tyagarajan – Chief Technical & Development Officer
Conference Call Participants
Steven Finkelstein
Daniel George
Neal Shore
Yigal Nochomovitz – Citigroup Inc., Research Division
Imogen Mansfield – Cantor Fitzgerald & Co., Research Division
Oliver McCammon – LifeSci Capital, LLC, Research Division
Andres Maldonado – H.C. Wainwright & Co, LLC, Research Division
Brian Kemp Dolliver – Brookline Capital Markets, LLC, Research Division
Sudan Loganathan – Stephens Inc., Research Division
Stephen Willey – Stifel, Nicolaus & Company, Incorporated, Research Division
Alec Stranahan – BofA Securities, Research Division
Presentation
Operator
Good afternoon, and welcome to the Candel Therapeutics conference call, where the company will be discussing extended follow-up data from the Phase III clinical trial in patients with localized prostate cancer following an oral plenary presentation at the 2026 American Urological Association Annual Meeting with subsequent Q&A from Candel management and their guests, thought leader physicians.
[Operator Instructions]
Please be advised that this call is being recorded. You can find information on a replay of the call and further information related to today’s announcements on the Candel Therapeutics website at candeltx.com.
At this time, I would like to turn the call over to Ted Jenkins, Vice President, Investor Relations and Business Development at Candel Therapeutics. Mr. Jenkins, please go ahead.
Ted Jenkins
Thank you, operator. Good afternoon, everyone, and thank you for joining us on today’s call. Earlier today, the company presented extended follow-up data from the Phase III clinical trial in patients with intermediate to high-risk localized prostate cancer during an oral plenary presentation at the 2026 American Urological Association Annual Meeting in Washington, D.C. We are pleased to conduct a public
